Your browser doesn't support javascript.
loading
Micronutrients for Attention-Deficit/Hyperactivity Disorder in Youths: A Placebo-Controlled Randomized Clinical Trial.
Johnstone, Jeanette M; Hatsu, Irene; Tost, Gabriella; Srikanth, Priya; Eiterman, Leanna P; Bruton, Alisha M; Ast, Hayleigh K; Robinette, Lisa M; Stern, Madeline M; Millington, Elizabeth G; Gracious, Barbara L; Hughes, Andrew J; Leung, Brenda M Y; Arnold, L Eugene.
Afiliação
  • Johnstone JM; Oregon Health & Science University, Portland; National University of Natural Medicine, Helfgott Research Institute, Portland, Oregon. Electronic address: jojeanet@ohsu.edu.
  • Hatsu I; The Ohio State University, Columbus.
  • Tost G; Oregon Health & Science University, Portland.
  • Srikanth P; OHSU-Portland State University School of Public Health, Oregon.
  • Eiterman LP; The Ohio State University, Columbus.
  • Bruton AM; Oregon Health & Science University, Portland.
  • Ast HK; Oregon Health & Science University, Portland.
  • Robinette LM; The Ohio State University, Columbus.
  • Stern MM; The Ohio State University, Columbus.
  • Millington EG; University of Lethbridge, Alberta, Canada.
  • Gracious BL; The Ohio State University, Columbus; Orange Park Medical Center, Florida, and the Edward Via College of Osteopathic Medicine, Spartanburg, South Carolina.
  • Hughes AJ; Oregon Health & Science University, Portland.
  • Leung BMY; University of Lethbridge, Alberta, Canada.
  • Arnold LE; The Ohio State University, Columbus.
J Am Acad Child Adolesc Psychiatry ; 61(5): 647-661, 2022 05.
Article em En | MEDLINE | ID: mdl-34303786
OBJECTIVE: To evaluate whether micronutrients (vitamins/minerals) benefit attention-deficit/hyperactivity disorder (ADHD) and irritability in a North American pediatric sample. METHOD: A 3-site, 8-week, placebo-controlled, randomized clinical trial of micronutrients was conducted in nonmedicated children aged 6 to 12 years with ADHD and at least 1 impairing irritability symptom by parent report on the Child and Adolescent Symptom Inventory-5 (CASI-5). A priori-defined primary outcomes were Clinical Global Impression-Improvement (CGI-I) (CGI-I of 1 or 2 = treatment responder) and parent-rated CASI-5 composite score of ADHD, oppositional defiant, disruptive mood dysregulation, and peer conflict symptoms, including impairment scores. RESULTS: Of 135 randomized (mean age 9.8 years), 126 youths (93%) comprised the modified intention-to-treat population. Blinding was maintained. For the CGI-I, 54% of the micronutrient and 18% of the placebo group were responders (risk ratio = 2.97, 97.5% CI = 1.50, 5.90, p < .001). CASI-5 composite scores improved significantly for both groups (p < .01), with a mean change of -0.31 (95% CI = -0.39, -0.23) in the micronutrient group and a mean change of -0.28 (95% CI = -0.38, -0.19) in the placebo group. However, the between-group difference was not significant (mean change = -0.02; 97.5% CI = -0.16, 0.12, effect size = 0.07, p = .70). The micronutrient group grew 6 mm more than the placebo group (p = .002). No serious adverse events or clinically significant changes from baseline in blood and urine tests occurred. CONCLUSION: Micronutrients showed global benefit over placebo by blinded clinician rating, but not by parent-report CASI-5 composite rating in a population with ADHD and irritability. Micronutrients showed greater height growth. Micronutrients were well tolerated, and the majority of participants adhered to the number of capsules prescribed. This randomized controlled trial replicates safety and efficacy reported for ADHD in 2 smaller trials of a similar formula containing all vitamins and known essential minerals in amounts between the Recommended Dietary Allowance and Upper Tolerable Intake Level. CLINICAL TRIAL REGISTRATION INFORMATION: Micronutrients for ADHD in Youth (MADDY) Study; https://clinicaltrials.gov; NCT03252522.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno do Deficit de Atenção com Hiperatividade Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Humans Idioma: En Revista: J Am Acad Child Adolesc Psychiatry Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno do Deficit de Atenção com Hiperatividade Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Humans Idioma: En Revista: J Am Acad Child Adolesc Psychiatry Ano de publicação: 2022 Tipo de documento: Article